News | Coronavirus (COVID-19) | March 16, 2020| Dave Fornell, Editor

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

The European Society of Cardiology (ESC) is recommending in novel coronavirus (COVID-19) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension. 

March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus (COVID-19, and now clinically referred to as SARS‐CoV‐2) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension

Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak.

According to case fatality rates reported by the American College of Cardiology (ACC) in COVID-19 patients, comorbid patients have materially higher than the average population. The ACC said hypertension elevates patient mortality risk to 6 percent. Read more on ACC COVID-19 recommendations for the cardiovascular care team.

The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.

Based on initial reports on COVID-19 patients in China and subsequent evidence since the outbreak, arterial hypertension may be associated with increased risk of mortality in hospitalized COVID-19 infected subjects. There was a hypothesis  suggesting this might be a potential adverse effect of ACE-i or ARBs. 

"It has been suggested, especially on social media sites, that these commonly used drugs may increase both the risk of infection and the severity of SARS-CoV2," explained Prof. Giovanni de Simone, chair of the ESC Council on Hypertension, who wrote the statement. "The concern arises from the observation that, similar to the coronavirus causing SARS, the COVID-19 virus binds to a specific enzyme called ACE2 to infect cells, and ACE2 levels are increased following treatment with ACE-i and ARBs." 

ESC said in the statement that because of the social media-related amplification, patients taking these drugs for their high blood pressure and their doctors have become increasingly concerned, and, in some cases, have stopped taking their ACE-I or ARB medications.

"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it. Indeed, there is evidence from studies in animals suggesting that these medications might be rather protective against serious lung complications in patients with COVID-19 infection, but to date there is no data in humans," he said.

"There has been a lot of talk about the molecular and pathophysiology basis of the virus being mediated by the ACE-II receptors," said Thomas Maddox, M.D., MSc, FACC, the chairman of the American College of Cardiology (ACC) Science and Quality Committee, which recently created the ACC document on novel coronavirus (COVID-19) clinical guidance for the cardiovascular care team. "They are primarily in the lung, and that is why many people obviously have the pulmonary symptoms that are showing, but we know they are in the heart and intestine as well. We have started hearing reports of patients both domestically [in the U.S.] and overseas where they started to show signs of recovery from the lung disease and then all of a sudden appear to develop myocarditis or cardiomyopathy, and in some cases it is fatal."

He explained there was thinking that in the the expression of ACE-IIs, ACE-I inhibitors or ARBs might be able to inhibited the viral transport into the cells. However, the mechanisms behind the interactions of ACE-II and the ACI-Is and ARBs is very complex and there is no clear evidence that these drugs help inhibit, or aid the disease.

Read the related article COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues.

This includes some background information on the ACE receptors — VIDEO: The Latest Data on COVID-19 and Cardiovascular Disease

Watch the VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D., which discusses this subject in more detail.

Watch the VIDEO: Cancelling Non-essential Cardiac Procedures During the COVID-19 Outbreak — an interview with SCCT President Ehtisham Mahmud, M.D.,

For more information: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang

 

Related Cardiology Related COVID-19 Content:

ACC COVID-19 recommendations for the cardiovascular care team

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

The Cardiac Implications of Novel Coronavirus

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Deployment of Health IT in China’s Fight Against the COVID-19 Epidemic

Emerging Technologies Proving Value in Chinese Coronavirus Fight

Radiologists Describe Coronavirus CT Imaging Features

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia 

 

Additional COVID-19 Resources for Clinicians:

   ACC COVID-19 Hub page   

   Johns Hopkins Coronavirus Resource Center with inteavtive map of cases in U.S. and worldwide 

   World Health Organization (WHO) COVID-19 situation reports

   World Health Organization (WHO) coronavirus information page

   U.S. Food and Drug Administration (FDA) COVID-19 information page

   Centers for Disease Control (CDC) COVID-19 information page

   Centers for Medicare and Medicaid Services (CMS) frequently asked questions and answers (FAQs) for healthcare providers regarding COVID-19 related payments

Related Content

Part of a CDC inforgraphic on MIS-C based on reports from U.S. cases March-May 2020.[2] The full inforgraphic can be found at https://www.cdc.gov/coronavirus/2019-ncov/covid-data/infographic-mis-c.html #COVID19

Part of a CDC inforgraphic on MIS-C based on reports from U.S. cases March-May 2020.[2] The full inforgraphic can be found at https://www.cdc.gov/coronavirus/2019-ncov/covid-data/infographic-mis-c.html

News | Coronavirus (COVID-19) | August 07, 2020
August 7, 2020 — The National Institutes of Health (NIH) announced research funding to encourage the development of a
Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis. #COVID19 #SARScov2 #Impella

Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis.

Feature | Coronavirus (COVID-19) | August 05, 2020 | Dave Fornell, Editor
August 5, 2020 — The U.S.
Left, a 3-D rendering of a heart from a cardiac CT exam. Right, a lung-CT exam showing the heart and ground glass lesions in the lungs of a COVID-19 patient. CT has become a front-line imaging modality in the COVID era because it offers both cardiac and lung information to help determine a patients disposition with chest pain, COVID-19 and COVID-caused myocarditis and pulmonary embolism.

Left, a 3-D rendering of a heart from a cardiac CT exam. Right, a lung-CT exam showing the heart and ground glass lesions in the lungs of a COVID-19 patient. CT has become a front-line imaging modality in the COVID era because it offers both cardiac and lung information to help determine a patients disposition with chest pain, COVID-19 and COVID-caused myocarditis and pulmonary embolism.

Feature | Coronavirus (COVID-19) | July 28, 2020 | Dave Fornell, Editor
July 28, 2020 — The use of cardiova...
Figure B — Top panel, neutrophils noted in collections within small vessels (blue arrow), plump endothelial cells (yellow arrowhead) and a single perivascular dying myocyte (blue arrowhead). Bottom panel, single myocyte undergoing degeneration (blue arrowhead) and plump endothelial cell (yellow arrowhead). Figure C — Electron microscopy, showing particles of SARS-CoV-2 virus present within a cardiac endothelial cell (blue arrowheads), but not present in neighboring cardiac myocyte. #COVID19

Figure B — Top panel, neutrophils noted in collections within small vessels (blue arrow), plump endothelial cells (yellow arrowhead) and a single perivascular dying myocyte (blue arrowhead). Bottom panel, single myocyte undergoing degeneration (blue arrowhead) and plump endothelial cell (yellow arrowhead). Figure C — Electron microscopy, showing particles of SARS-CoV-2 virus present within a cardiac endothelial cell (blue arrowheads), but not present in neighboring cardiac myocyte (left side of image). Images from Circulation.

Feature | Coronavirus (COVID-19) | July 23, 2020
July 23, 2020 - A series of autopsies conducted by Louisiana State University (LSU) Health New Orleans pathologists s
The impact of COVID-19 on the healthcare industry.

Getty images

News | Coronavirus (COVID-19) | July 16, 2020
July 16, 2020 – Frost and Sullivan’s recent analysis, Post-Pandemic Global Healthcare Market Outlook, 2020, forecasts
Cardiac MRI for four children with clinical diagnosis of acute myocarditis in the setting of COVID-19–related Kawasaki-like symptoms of Multisystem Inflammatory Syndrome in Children (MIS-C). Cardiac MRI of COVID pediatric COVID-19 patients.

Cardiac MRI for four children with clinical diagnosis of acute myocarditis in the setting of COVID-19–related Kawasaki-like symptoms of MIS-C. The top panel demonstrates minimal pericardial effusion on cine images. The second panel demonstrates increased T2-STIR signal intensity with average ratios between myocardium and muscle > 2 in patient 2 (12-year-old male), patient 3 (11-year-old female) and patient 4 (6-year-old female). The third panel demonstrates abnormal native-T1 mapping, which was > 1,100 ms in patients 2, 3 and 4 and normal in patient 1 (8-year-old female). The bottom panel demonstrates absence of late gadolinium enhancement (LGE) in patients 2 and 3. Myocardial null times were recognized as too short in patient 4 but could not be repeated due to lack of further patient cooperation; however review of Look Locker images and additional sequences revealed no LGE. Image courtesy of RSNA.

Feature | Coronavirus (COVID-19) | July 09, 2020
July 8, 2020 — Cardiac...
Older Critically Ill COVID-19 Patients May Have Increased Risk of Bradycardia With Lopinavir and Ritonavir.

Photo copyright American Heart Association, used with permission.

Feature | Coronavirus (COVID-19) | July 09, 2020
July 9, 2020 — Older, critically ill patients with COVID-19 (SARS-CoV-2) who received a combination of the antiretrov
Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), has been the target of threats over his suggestions on how to contain the spread of coronavirus in the U.S. Photo by Jonathan Wyett, U.S. Department of State

Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), has been the target of threats over his suggestions on how to contain the spread of coronavirus in the U.S. Photo by Jonathan Wyett, U.S. Department of State

News | Coronavirus (COVID-19) | July 07, 2020 | Dave Fornell, Editor
July 7, 2020 — In the face of the coronavirus pandemic, public health officials worldwide are working tirelessly to s
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

Feature | Coronavirus (COVID-19) | June 30, 2020
In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure
Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

Clive Svendsen, Ph.D., director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, at work in his laboratory. Photo by Cedars-Sinai.

News | Coronavirus (COVID-19) | June 30, 2020
June 30, 2020 — A...